Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19305055 | 0.75 | ESR1 (0.47) | SMN1; SMN2MAPTNPC1RAB9AHPGD | |
| SCHEMBL10109414 | 0.72 | NOS3 (0.43) | SMN1; SMN2MAPTNPC1RAB9AHPGD | |
| Ammonia Solution, Strong SCHEMBL22730063 | 0.71 | SLC6A2 (0.47) | SMN1; SMN2MAPTNPC1RAB9AHPGD | |
| SCHEMBL17765400 | 0.69 | TP53 (0.44) | TP53NPSR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17637160 | 0.67 | ESR1 (0.54) | ABCB1ALDH1A1 | |
| SCHEMBL1615072 | 0.67 | ABL1 (0.63) | SMN1; SMN2MAPTNPC1RAB9AHPGD | |
| SCHEMBL11895545 | 0.66 | MAPT (0.44) | SMN1; SMN2MAPTNPC1RAB9AHPGD | |
| SCHEMBL4423401 | 0.66 | ESR2 (0.57) | SMN1; SMN2MAPTNPC1RAB9AHPGD | |
| SCHEMBL28414867 | 0.65 | ESR2 (0.53) | SMN1; SMN2MAPTNPC1RAB9AHPGD | |
| SCHEMBL570649 | 0.64 | KDM4E (0.67) | LMNAABCB1CYP3A4CYP19A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| EP-2074102-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008043567-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043567-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | ESR1, GPER1, ESR2 | SMN1; SMN2 2790/4885MAPT 3272/4885NPC1 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.